|
|
WELCOME TO YOUR NEW VYVANSE® ENGAGEMENT EXPERIENCE
|
|
Dear Dr. {Last name},
|
|
Though there are changes ahead as the VYVANSE® patent expires in June 2024, Takeda is committed to ensuring continued easy, on-demand support through VYVANSE.ca and your new Customer Experience Specialist (CES), {CES NAME}.
|
|
Your CES and the VYVANSE.ca portal are here to support your practice moving forward. {CES NAME} will be reaching out to you soon to schedule a meeting to provide you with more information and to answer any questions you may have.
|
|
Get connected at VYVANSE.ca
|
|
|
VYVANSE.ca is your easy, on-demand resource for information about VYVANSE, including:
|
|
Key information about VYVANSE, such as dosing and clinical study results
|
|
|
Downloadable patient and HCP resources
|
|
|
Information about the innoviCares program (available in all provinces and territories except Quebec)
|
|
|
Takeda’s new self-serve portal – book meetings, order materials, ask questions, and more!
|
|
|
|
|
|
The innoviCares program uses 3 simple steps to give your patients the option to remain on VYVANSE if deemed medically appropriate.
|
| 1. |
You or the patient can download the innoviCares payment card. |
| 2. |
The patient presents the card to their pharmacist along with your prescription. |
| 3. |
The patient requests VYVANSE by name at their pharmacy. |
|
|
We understand that this is a new way for you to engage with Takeda and encourage you to contact {CES NAME AND EMAIL} if you have any immediate questions. As always, Takeda is committed to supporting you and your patients living with ADHD.
|
|
|
|
|
|
|
|
Indications and clinical use:1
VYVANSE (lisdexamfetamine dimesylate) capsules and chewable tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
VYVANSE should not be used in children under 6 years of age and is not indicated for use in the geriatric population (>65 years of age). Subjects over 55 years of age were excluded from the ADHD clinical trials. VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. The physician who elects to use VYVANSE for extended periods should periodically re-evaluate the long-term usefulness of the drug.
Consult the product monograph at www.takeda.com/en-ca/vyvansepm for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.
The Product Monograph is also available by calling Takeda Canada Inc. at 1-800-268-2772.
Reference:
1. Takeda Canada Inc. VYVANSE Product Monograph. March 20, 2024.
|
|
Is the content of this email relevant to you?
|
|
|
|
|
|
Takeda Canada Inc.
Bay Adelaide Centre
22 Adelaide Street West, Suite 3800
Toronto, ON M5H 4E3
www.takeda.com/en-ca
|
VYVANSE and  are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc.
|
TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited,
used under license.
|
© 2024 Takeda Pharmaceutical Company Limited. All rights reserved.
PRMCDA/CA/Vyv/0144
|
|
This email is intended for Canadian healthcare professionals only.
|
If you wish to stop receiving email notifications from Takeda Canada Inc., unsubscribe.
You can also learn about the information that we may process about you and how we use your information here.
|
|
|
